Home Newsfeeds Stifel Maintains Hold on Snap, Lowers Price Target to $9

Stifel Maintains Hold on Snap, Lowers Price Target to $9

Stifel analyst Mark Kelley maintains Snap (NYSE:SNAP) with a Hold and lowers the price target from $14 to $9.

byBenzinga Newsdesk

October 21, 2022

1 minute read

Stifel analyst Mark Kelley maintains Snap (NYSE:SNAP) with a Hold and lowers the price target from $14 to $9.

Analyst Ratings

Keybanc Maintains Overweight Rating for Palo Alto Networks: Here’s What You Need To Know

By Benzinga Insights

October 13, 1:00 PM

Keybanc has decided to maintain its Overweight rating of Palo Alto Networks (NASDAQ:PANW) and raise its price target…

PANW

Bioventus And 3 Other Stocks Under $5 Insiders Are Buying

By Lisa Levin

August 23, 9:23 AM

The Dow Jones closed lower by 175 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

BVS

What Does Cheniere Energy’s Debt Look Like?

By Benzinga Insights

March 1, 2:30 PM

Shares of Cheniere Energy Inc. (AMEX:LNG) decreased by 8.34% in the past three months. Before having a look at the importance of debt, let's look at how much debt Cheniere Energy has.

LNG

Aprea Therapeutics Announces Submission Of IND Application For APR-1051, A Next Generation WEE1 Kinase Inhibitor

By Benzinga Newsdesk

February 6, 9:03 AM

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an

APRE

Stifel Maintains Hold on Snap, Lowers Price Target to $9

Related Posts

Keybanc Maintains Overweight Rating for Palo Alto Networks: Here’s What You Need To Know

Bioventus And 3 Other Stocks Under $5 Insiders Are Buying

What Does Cheniere Energy’s Debt Look Like?

Aprea Therapeutics Announces Submission Of IND Application For APR-1051, A Next Generation WEE1 Kinase Inhibitor